Aligos Therapeutics, Inc. (ALGS) Current Ratio
- Current ratio · latest quarter: Value 2.19×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.19× | Current assets / current liabilities. $62.13M ÷ $28.34M ≈ 2.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 62.13M USD | Assets, Current |
| Current obligations | 28.34M USD | Liabilities, Current |
| Cash and equivalents | 30.38M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 27.78M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 6.43M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $62.13M | $28.34M | $30.38M | (m) | $27.78M | (m) | $6.43M | (m) | 2.19× |
| 2026-03-31 | $59.63M | $23.32M | $29.98M | (m) | (m) | (m) | $7.64M | (m) | 2.56× |
| 2025-12-31 | $82.86M | $21.23M | $18.30M | (m) | (m) | (m) | $3.98M | (m) | 3.90× |
| 2025-09-30 | $103.44M | $21.99M | $41.95M | (m) | (m) | (m) | $4.65M | (m) | 4.70× |
| 2025-06-30 | $127.94M | $20.27M | $18.66M | (m) | (m) | (m) | $3.94M | (m) | 6.31× |
| 2025-03-31 | $143.21M | $18.95M | $73.76M | (m) | (m) | (m) | $4.46M | (m) | 7.56× |
| 2024-12-31 | $62.14M | $21.74M | $37.00M | (m) | (m) | (m) | $2.57M | (m) | 2.86× |
| 2024-09-30 | $79.82M | $20.96M | $35.33M | (m) | (m) | (m) | $2.74M | (m) | 3.81× |
| 2024-06-30 | $99.57M | $23.56M | $45.08M | (m) | (m) | (m) | $6.82M | (m) | 4.23× |
| 2024-03-31 | $118.06M | $18.88M | $24.15M | (m) | (m) | (m) | $2.84M | (m) | 6.25× |
| 2023-12-31 | $141.08M | $23.91M | $135.70M | (m) | (m) | (m) | $2.52M | (m) | 5.90× |
| 2023-09-30 | $74.64M | $22.47M | $70.43M | (m) | (m) | (m) | $2.94M | (m) | 3.32× |
| 2023-06-30 | $94.24M | $27.23M | $90.83M | (m) | (m) | (m) | $3.24M | (m) | 3.46× |
| 2023-03-31 | $109.43M | $28.08M | $78.67M | (m) | (m) | (m) | $2.82M | (m) | 3.90× |
| 2022-12-31 | $133.54M | $33.13M | $81.35M | (m) | (m) | (m) | $4.74M | (m) | 4.03× |
| 2022-09-30 | $150.09M | $30.54M | $86.44M | (m) | (m) | (m) | $2.93M | (m) | 4.91× |
| 2022-06-30 | $167.69M | $31.65M | $71.17M | (m) | (m) | (m) | $2.76M | (m) | 5.30× |
| 2022-03-31 | $195.08M | $41.36M | $104.56M | (m) | (m) | (m) | $3.75M | (m) | 4.72× |
| 2021-12-31 | $204.42M | $38.96M | $186.82M | (m) | (m) | (m) | $3.02M | (m) | 5.25× |
| 2021-09-30 | $248.67M | $34.78M | $239.73M | (m) | (m) | (m) | $2.60M | (m) | 7.15× |
| 2021-06-30 | $196.64M | $30.10M | $187.65M | (m) | (m) | (m) | $1.59M | (m) | 6.53× |
| 2021-03-31 | $219.83M | $25.23M | $200.36M | (m) | (m) | (m) | $2.81M | (m) | 8.71× |
| 2020-12-31 | $250.02M | $30.27M | $220.38M | (m) | (m) | (m) | $3.31M | (m) | 8.26× |
| 2020-09-30 | $73.69M | $19.98M | $31.82M | (m) | (m) | (m) | $7.68M | (m) | 3.69× |
| 2019-12-31 | $120.23M | $13.82M | $69.56M | (m) | (m) | (m) | $3.77M | (m) | 8.70× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |